Literature DB >> 26834401

Outcome and erectile function following treatment of priapism: An institutional experience.

Dilip Kumar Pal1, Deepak Kumar Biswal1, Bastab Ghosh1.   

Abstract

INTRODUCTION: Priapism has a devastating consequence on the sexual function of men if not promptly managed. We are presenting our experience of the treatment of priapism and the status of sexual function even following successful detumescence achieved after treatment.
MATERIALS AND METHODS: Nineteen patients, who presented with priapism from January 2012 to December 2014, were included in the study. After obtaining a detailed history; color Doppler ultrasonography of penis and blood gas analysis of the initial corporal aspirate were done to ascertain the type of priapism. Standard protocol in our institute for management of priaprism was to start with conservative treatment by corporal aspiration and intracorporeal injection (ICI) of phenylephrine. On the failure of conservative management, distal shunts were performed. Proximal shunts were performed on the failure of distal shunt procedures. Erectile function was evaluated with International Index of Erectile Function-5 questionnaire on admission and during follow-up.
RESULTS: All the patients had ischemic type priapism. Age of the patients ranged from 22 to 55 years. Duration of priapism varied from 20 to 480 h (mean 96.7). Etiologies attributed were; over-the-counter sildenafil use, chlorpromazine, opium intake and intracorporeal papaverine injection, chronic myeloid leukemia, and idiopathic. Five patients had preserved erectile function during follow-up. Preservation of normal erectile function following aspiration and ICI, proximal and distal shunt procedures were 66.7%, 18.1% and 20%, respectively.
CONCLUSION: Patients with late presentation and those patients requiring higher treatment modalities (e.g., proximal shunts) for achieving detumescence will subsequently have a poor erectile function. These patients should be counseled about the early penile prosthesis placement during initial surgical management.

Entities:  

Keywords:  Erectile dysfunction; impotence; penile implant; penile prosthesis; priapism

Year:  2016        PMID: 26834401      PMCID: PMC4719511          DOI: 10.4103/0974-7796.165717

Source DB:  PubMed          Journal:  Urol Ann        ISSN: 0974-7796


INTRODUCTION

Priapism although uncommon, has a devastating consequence on the sexual function of men if not promptly managed. Although various treatment modalities for ischemic priapism achieves the reversal of ischemic episode and complete detumescence of penis, with longer duration of priapism (>24 h), causes irreversible damage in the ultrastructure of the erectile tissue and later poor erectile function.[1] Many studies reported the results of various treatment modalities in priapism. However, most were retrospective in nature and having small number of patients. In those studies, the management protocol was also not clearly defined. We are presenting our experience on the treatment of priapism and the status of sexual function even following successful detumescence achieved after treatment.

MATERIALS AND METHODS

It was a prospective, observational study conducted in a tertiary care center. After the institute had obtained the ethical board clearance, we included all the patients who were presented with priapism to our department from January 2012 to December 2014. A total of nineteen patients were studied. On admission, detailed history of duration of the priapism, presence of penile pain, previous similar episodes or any treatment for priapism, drug intake, local or perineal trauma, blood dyscrasia, neurologic conditions, and erectile dysfunction (ED) were taken. In all the patients, color Doppler ultrasonography (CDU) of penis and blood gas analysis of the initial corporal aspirate were performed after the admission to differentiate the type of priapism (high flow or ischemic). For ischemic priapism, our protocol was to start immediate local treatment to resolve the ischemic environment. Initial corporal aspiration and irrigation were followed by intracorporeal injection (ICI) of phenylephrine (100 µg/ml) as per the requirement, up to a maximum dose of 1000 µg. If penis failed to detumescent after giving 1-h of conservative management, we proceeded for percutaneous distal shunt under local anesthesia (Winter shunt). We checked for penile detumescence following Winter shunt. If penile detumescence was not achieved within 30 min of Winter shunt, we performed open distal shunt under general anesthesia as soon as possible. Initially, we planned for Al-Ghorab shunt by glans incision and distal corporotomy. If all clots inside the corpora could not be evacuated by squeezing and saline irrigation, we performed “corporal snake” maneuver by introducing dilators through distal corporotomy. If erection persists following distal shunts, we repeated blood gas analysis of the corporal aspirate and CDU of the penis to check the resolution of the ischemic event. If it showed a failure of the distal shunt, we performed proximal shunt as soon as possible. In the postoperative period, frequent check for penile detumescence was performed. If failed, we repeated the CDU and did magnetic resonance imaging (MRI) of the penis. For patients who showed extensive corporal fibrosis on MRI, we advised for early penile prosthesis insertion. Follow-up was done at outpatient service. Erectile function was evaluated with the International Index of Erectile Function-5 (IIEF-5) questionnaire. Baseline erectile function score was recorded on admission and further scores were recorded at 6-month intervals during follow-up.

RESULTS

Age of the patients ranged from 22 to 56 years (mean 33.9). Duration of priapism varied from 20 to 480 h (mean 96.7). Etiologies attributed were; over-the-counter sildenafil use, chlorpromazine, opium intake and intracorporeal papaverine injection, and chronic myeloid leukemia [Table 1]. One newly married young patient reported priapism following coitus. He had no previous history of ED or priapism or prolonged erection episodes. Two patients had diabetes as well as hypertension as additional comorbidities. Rest of the patients had no medical comorbidities.
Table 1

Etiologies of priapism

Etiologies of priapism All patients had ischemic priapism, confirmed by CDU and blood gas analysis of the initial corporal aspirate. With initial intracorporeal aspiration and ICI of phenylephrine (total dose range: 600–1000 µg) penile detumescence was achieved in three patients. In two hypertensive patients, only intracorporeal aspiration was performed and phenylephrine injection was omitted. Fourteen patients had residual tumescence after bilateral Winter shunt procedure [Figure 1a], in those patients open distal shunts were performed. In six patients, Al-Ghorab shunt was performed. In eight patients “corporal snake” maneuver was performed [Figure 1b]. Al-Ghorab shunt was successful in four out of six patients and “corporal snake” maneuver was successful in five out of eight patients in achieving detumescence and reversing ischemic priapism. Five patients had persistent tumescence following distal shunt procedure on the next day. Proximal shunts (Quackles shunt) were performed in those patients. In all the patients, ischemic priapism event was reversed and successfully confirmed by CDU. Out of which three patients achieved complete detumescence, one patient had partial detumescence, and another had persistent priapism. In the case of persistent priapism, on further evaluation with the blood gas analysis of corporal aspirate and color Doppler ultrasound, showed conversion to high flow priapism due to the proximal shunt. In the other case of partial detumescence, the cause was due to fibrosis of the corpora as a result of prolonged duration of priapism (480 h) confirmed by MRI of the penis. MRI showed diffuse heterogenous low signal intensities on T2-weighted images in the corpora and after gadolinium injection there was no enhancement in the fibrotic regions in T1-weighted postcontrast images. Success rate observed in various treatment modalities depicted in Table 2.
Figure 1

(a) Winter shunt. (b) Corporal snake maneuver with dilator passed into the corpora through glans incision

Table 2

Success rate of treatment modalities

(a) Winter shunt. (b) Corporal snake maneuver with dilator passed into the corpora through glans incision Success rate of treatment modalities Urethral injury occurred in one patient during Al-Ghorab shunt, which is repaired intraoperatively over a urethral catheter. Another patient following “corporal snake” maneuver developed cavernositis and failure of the shunt, which was managed conservatively. One patient had partial penile skin necrosis. Mean follow-up time was 13.6 months (range: 6–31). Mean IIEF-5 score before the event was 24.0 (range: 25–17). During the follow-up, mean IIEF-5 score was 13.1 (range: 25–5) [Table 3]. Out of nineteen sexually active men, only two patients had mild ED before the priapism episode. Following priapism episode, only five patients preserved normal erectile function. We treated the patients who complained ED during the follow-up with tadalafil (10 to 20 mg as per requirement on demand). With tadalafil treatment, only two patients had improvement in their erectile function. Rest 12 patients had no improvement in erectile function with tadalafil during the follow-up. Mean duration of priapism in patients who preserved the prepriapism erectile function was 32.8 h (range: 22–40), whereas in patients who had declined erectile function was 119.6 h (range: 20–480) (P = 0.005, Mann–Whitney U-test). Two of the three patients (66.7%) treated with aspiration and ICI/aspiration alone had normal erectile function following the treatment. Preservation of normal erectile function following proximal and distal shunt procedures are 18.1% and 20%, respectively.
Table 3

Summary of interventions done and result

Summary of interventions done and result

DISCUSSION

Priapism is an acute condition, which needs prompt evaluation and appropriate management to maximize erectile function outcomes. It is defined as “full or partial erection that continues more than 4 h beyond sexual stimulation and orgasm or is unrelated to sexual stimulation.”[2] The term priapism was derived from Greek god “Priapus,” who was worshiped as the god of fertility and had giant phallus in sculptures.[3] In a population-based, retrospective cohort study, the incidence of priapism in the general population was reported to be 1.5 per 100,000 person-years.[4] Recent reports of incidence vary widely from 0.13 to 5.34 per 100,000 person-years.[56] Pathophysiologically, it is classified into two types; ischemic and nonischemic type. An intermittent variant of ischemic type is called “stuttering” priapism.[78] Ischemic priapism is the most common form of priapism (>95%) in all priapism episodes. Although most ischemic priapisms are idiopathic without any precipitating cause, various other etiologies have been attributed for ischemic priapism. Those are drug-induced, hematologic (most common: Sickle cell disease, other hemoglobinopathies), thrombophilia states (protein C and other thrombophilias, lupus), hyperviscosity states (hyperleukocytosis, polycythemia), and central nervous system disorders. Some are idiopathic.[910111213] In our series, all the cases were of ischemic type with varied etiologies. Mean duration of priapism was 96.7 h. Late presentation to medical facilities was due to patient's embarrassment and poor knowledge about the condition attributed to this prolonged duration of priapism at presentation. Distinction of the type of priapism is paramount as ischemic type needs immediate treatment to preserve good sexual function. Color Doppler Ultrasound and blood gas analysis of corporal aspirate has been advocated initially to differentiate the type of priapism.[2111415] In our series, CDU accurately diagnosed the ischemic priapism and associated cavernous thrombosis in all cases. In postoperative period, CDU is important for diagnosing the patency of shunt in doubtful cases.[1416] In case of ischemic priapism, immediate penile aspiration should be initiated irrespective of the cause without delay.[8] In our study, aspiration with ICI of phenylephrine successfully reversed ischemic priapism in three out of six patients who had presented within 48 h of onset. Overall success rate was 15.7%. Reported success rate of aspiration alone is about 30% and intracavernous injection with or without aspiration ranges from 43% to 81%.[17] In our series, the lower success rate was probably due to delayed presentation to our institution as it was a tertiary center. Winter shunt was successful only in three patients out of sixteen patients in whom the procedure was performed and others (81.3%) required additional shunt procedures. Nixon et al. reported that 86% of their patients treated with a Winter shunt required a second shunt procedure.[18] However, in another report, success rate of Winter shunt was about 66%.[17] Our result and other reports show although Winter shunt is less invasive; the results are poor with this shunt procedure. Open distal shunts such as Al-Ghorab or “corporal snake” maneuver were successful in nine out of fourteen patients to achieve detumescence (64.3% success rate). One patient with “corporal snake” maneuver developed cavernositis and closure of shunt in the 3rd postoperative day and was managed conservatively. Al-Ghorab shunt has a reported success rate of about 74%.[17] In the rest of five patients who had failed distal shunts underwent bilateral Quackles shunt, which was successful in three patients. One developed persistent, partial tumescence due to conversion to high flow type, confirmed by Doppler ultrasound. Another patient who had priapism for about 20 days failed to achieve complete detumescence due to extensive corporal fibrosis. We used IIEF-5 questionnaire to evaluate ED in the treated patients before the priapism event and during the follow-up at a 6-month interval, which is a validated tool.[1920] Out of 19 sexually active men, only five patients preserved normal erectile function. This poor result was due to the prolong duration of priapism (without ED mean was 32.8 h, whereas patients having ED mean was 119.6 h). Zheng et al. in their series reported poor erectile function following the treatment of priapism (severe ED present in six out of eight patients) with the mean priapism duration of 96.33 h.[21] Gottsch et al. reported adequate erection in only six of the 35 patients following the treatment of priapism.[22] Tabibi et al. reported normal erectile function in 50%, 33.3%, and 25% of patients following Winter, Al-Ghorab, and Grayhack shunt, respectively. Mean duration of priapism was 51.12 h.[23] Our result also shows poor preservation of erectile function following shunt surgery. In our study, preservation of normal erectile function following proximal and distal shunt procedures were 18.1% and 20%, respectively. Natural history of untreated ischemic priapism or refractory priapism to interventions is severe penile fibrosis, which results in penile deformity, length loss, and ED. Some advocated immediate penile prosthesis insertion in priapism lasting more than 48–72 h due to future inevitable poor ED. The advantages over delay placement of prosthesis described are technically easier implant insertion and preserved penile length.[2425] However, high complications were associated with immediate prostheses such as 24% revision rate and 6% infection rate.[25] In our settings, due to nonavailability of an immediate prosthesis and financial constraints with the patients, we did not put any penile prosthesis. However, shunt surgery was done irrespective of the duration of priapism as it is reported that failure to maintain complete detumescence leads to increased corporal fibrosis and poor erectile function following priapism.[26] Limitation of this study is that it has fairly small number of patients.

CONCLUSION

Patients with late presentation and those patients requiring higher treatment modalities (e.g. proximal shunts) for achieving detumescence will subsequently have poor erectile function irrespective of the successful outcome in achieving complete detumescence of the penis. These patients should be counseled about the early penile prosthesis placement during initial surgical management.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  26 in total

Review 1.  Management of priapism: an update for clinicians.

Authors:  Helen R Levey; Robert L Segal; Trinity J Bivalacqua
Journal:  Ther Adv Urol       Date:  2014-12

2.  Incidence and clinical features of priapism in Japan: 46 cases from the Japanese diagnosis procedure combination database 2006-2008.

Authors:  T Sugihara; H Yasunaga; H Horiguchi; H Nishimatsu; S Matsuda; Y Homma
Journal:  Int J Impot Res       Date:  2011-03-31       Impact factor: 2.896

3.  Low-flow priapism: risk factors for erectile dysfunction.

Authors:  M S El-Bahnasawy; A Dawood; A Farouk
Journal:  BJU Int       Date:  2002-02       Impact factor: 5.588

4.  Incidence of priapism in emergency departments in the United States.

Authors:  Florian Roghmann; Andreas Becker; Jesse D Sammon; Miriam Ouerghi; Maxine Sun; Shyam Sukumar; Orchidee Djahangirian; Kevin C Zorn; Khurshid R Ghani; Giorgio Gandaglia; Mani Menon; Pierre Karakiewicz; Joachim Noldus; Quoc-Dien Trinh
Journal:  J Urol       Date:  2013-04-09       Impact factor: 7.450

Review 5.  Priapism: pathophysiology and the role of the radiologist.

Authors:  J E Halls; D V Patel; M Walkden; U Patel
Journal:  Br J Radiol       Date:  2012-09-06       Impact factor: 3.039

Review 6.  Unsatisfactory outcomes of prolonged ischemic priapism without early surgical shunts: our clinical experience and a review of the literature.

Authors:  Da-Chao Zheng; Hai-Jun Yao; Ke Zhang; Ming-Xi Xu; Qi Chen; Yan-Bo Chen; Zhi-Kang Cai; Mu-Jun Lu; Zhong Wang
Journal:  Asian J Androl       Date:  2012-08-27       Impact factor: 3.285

7.  The immediate insertion of a penile prosthesis for acute ischaemic priapism.

Authors:  David J Ralph; Giulio Garaffa; Asif Muneer; Alex Freeman; Rowland Rees; Andrew N Christopher; Sukbinder Minhas
Journal:  Eur Urol       Date:  2008-10-01       Impact factor: 20.096

Review 8.  Medical and surgical management of priapism.

Authors:  J Cherian; A R Rao; A Thwaini; F Kapasi; I S Shergill; R Samman
Journal:  Postgrad Med J       Date:  2006-02       Impact factor: 2.401

9.  The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction.

Authors:  E L Rhoden; C Telöken; P R Sogari; C A Vargas Souto
Journal:  Int J Impot Res       Date:  2002-08       Impact factor: 2.896

10.  Our experience in the treatment of priapism.

Authors:  Dmytro Vorobets; Oleg Banyra; Alexander Stroy; Alexander Shulyak
Journal:  Cent European J Urol       Date:  2011-06-02
View more
  8 in total

1.  Comparison of outcomes in malignant vs. non-malignant ischemic priapism: 12-year experience from a tertiary center.

Authors:  Manoj Kumar; Gaurav Garg; Ashish Sharma; Siddharth Pandey; Manmeet Singh; Satya Narayan Sankhwar
Journal:  Turk J Urol       Date:  2019-02-20

Review 2.  Conservative and medical treatments of non-sickle cell disease-related ischemic priapism: a systematic review by the EAU Sexual and Reproductive Health Panel.

Authors:  Andrea Salonia; Suks Minhas; Paolo Capogrosso; Kostas Dimitropolous; Giorgio Ivan Russo; Tharu Tharakan; Uros Milenkovic; Andrea Cocci; Luca Boeri; Murat Gül; Carlo Bettocchi; Joana Carvalho; Arif Kalkanlı; Giovanni Corona; Georgios Hatzichristodoulou; Hugh T Jones; Ates Kadioglu; Juan Ignacio Martinez-Salamanca; Vaibhav Modgil; Ege Can Serefoglu; Paolo Verze
Journal:  Int J Impot Res       Date:  2022-08-22       Impact factor: 2.408

Review 3.  Surgical and minimally invasive treatment of ischaemic and non-ischaemic priapism: a systematic review by the EAU Sexual and Reproductive Health Guidelines panel.

Authors:  S Minhas; A Salonia; U Milenkovic; A Cocci; R Veeratterapillay; K Dimitropoulos; L Boeri; P Capogrosso; N C Cilesiz; M Gul; G Hatzichristodoulou; V Modgil; G I Russo; T Tharakan; M I Omar; C Bettocchi; J Carvalho; Y Yuhong; G Corona; H Jones; A Kadioglu; J I Martinez-Salamanca; P Verze; E C Serefoglu
Journal:  Int J Impot Res       Date:  2022-09-23       Impact factor: 2.408

4.  Erectile function outcomes following surgical treatment of ischemic priapism.

Authors:  Moez Rahoui; Yassine Ouanes; Chaker Kays; Bibi Mokhtar; Kheireddine Mrad Dali; Ahmed Sellami; Sami Ben Rhouma; Yassine Nouira
Journal:  Ann Med Surg (Lond)       Date:  2022-04-29

Review 5.  Role of Penile Prosthesis in Priapism: A Review.

Authors:  Amit G Reddy; Laith M Alzweri; Andrew T Gabrielson; Gabriel Leinwand; Wayne J G Hellstrom
Journal:  World J Mens Health       Date:  2018-01       Impact factor: 5.400

6.  Leech Therapy for Treating Priapism: Case Report.

Authors:  Sayed Aladdin Asgari; Sadeq Rostami; Mojtaba Teimoori
Journal:  Iran J Public Health       Date:  2017-07       Impact factor: 1.429

7.  Daily tadalafil for the chronic phase of stuttering priapism: a case report.

Authors:  Paolo Massenio; Nicola D'Altilia; Francesca Sanguedolce; Giuseppe Carrieri; Luigi Cormio
Journal:  BMC Urol       Date:  2018-05-31       Impact factor: 2.264

8.  Priapism as the initial sign in hematologic disease: Case report and literature review.

Authors:  Luis Cuitláhuac Becerra-Pedraza; Luis Enrique Jiménez-Martínez; Iran Peña-Morfin; Rogelio Nava-Esquivel; Juan Alfredo Villegas-Martínez
Journal:  Int J Surg Case Rep       Date:  2018-01-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.